OCM

Summary

OCM (oncomodulin, HGNC:8105) is a protein-coding gene on chromosome 7p22.1, encoding Oncomodulin-1 (P0CE72). Has some calmodulin-like activity with respect to enzyme activation and growth regulation.

Oncomodulin is a high-affinity calcium ion-binding protein. It belongs to the superfamily of calmodulin proteins, also known as the EF-hand proteins. Oncomodulin is an oncodevelopmental protein found in early embryonic cells in the placenta and also in tumors.

Source: NCBI Gene 654231 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 29 total
• MANE Select transcript: NM_001097622

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:8105
Approved symbol	OCM
Name	oncomodulin
Location	7p22.1
Locus type	gene with protein product
Status	Approved
Aliases	OCM1
Ensembl gene	ENSG00000122543
Ensembl biotype	protein_coding
OMIM	164795
Entrez	654231

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000242104, ENST00000416608

RefSeq mRNA: 3 — MANE Select: NM_001097622 NM_001097622, NM_001391990, NM_001391991

CCDS: CCDS43548

Canonical transcript exons

ENST00000242104 — 4 exons

Exon	Start	End
ENSE00001649741	5886064	5886363
ENSE00001690920	5883890	5883999
ENSE00001711752	5880798	5880950
ENSE00001753601	5882493	5882625

Expression profiles

Bgee: expression breadth ubiquitous, 127 present calls, max score 85.70.

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.70	gold quality
amygdala	UBERON:0001876	71.28	gold quality
temporal lobe	UBERON:0001871	71.07	gold quality
granulocyte	CL:0000094	70.51	gold quality
cerebellar cortex	UBERON:0002129	67.58	gold quality
cerebellar hemisphere	UBERON:0002245	67.54	gold quality
cerebellum	UBERON:0002037	67.38	gold quality
blood	UBERON:0000178	66.00	gold quality
right hemisphere of cerebellum	UBERON:0014890	65.86	gold quality
lymph node	UBERON:0000029	62.95	gold quality
hypothalamus	UBERON:0001898	62.65	gold quality
Brodmann (1909) area 9	UBERON:0013540	62.59	gold quality
nucleus accumbens	UBERON:0001882	62.21	gold quality
spleen	UBERON:0002106	62.06	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	62.06	gold quality
Ammon’s horn	UBERON:0001954	61.30	gold quality
putamen	UBERON:0001874	61.02	gold quality
anterior cingulate cortex	UBERON:0009835	60.94	gold quality
leukocyte	CL:0000738	60.81	gold quality
superior frontal gyrus	UBERON:0002661	60.61	gold quality
right frontal lobe	UBERON:0002810	60.55	gold quality
brain	UBERON:0000955	60.06	gold quality
monocyte	CL:0000576	59.99	gold quality
primary visual cortex	UBERON:0002436	59.99	gold quality
cerebral cortex	UBERON:0000956	59.73	gold quality
caudate nucleus	UBERON:0001873	58.40	gold quality
frontal cortex	UBERON:0001870	58.23	gold quality
right testis	UBERON:0004534	57.96	gold quality
left testis	UBERON:0004533	57.66	gold quality
testis	UBERON:0000473	57.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.08

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting OCM, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-4317	98.49	67.09	987
HSA-MIR-1262	98.17	66.52	757
HSA-MIR-4701-3P	98.17	66.25	788
HSA-MIR-6736-5P	98.17	66.43	760
HSA-MIR-6757-5P	98.08	65.50	724
HSA-MIR-4421	97.99	64.89	701
HSA-MIR-4665-5P	97.91	67.69	1536
HSA-MIR-5699-3P	97.81	65.00	861
HSA-MIR-3127-5P	97.52	65.24	786
HSA-MIR-6514-3P	97.52	66.50	808
HSA-MIR-214-5P	97.34	66.50	617
HSA-MIR-509-3-5P	97.21	67.74	1517
HSA-MIR-509-5P	97.21	67.90	1512
HSA-MIR-4418	97.04	67.16	1372
HSA-MIR-12128	96.67	66.98	1471
HSA-MIR-6866-5P	96.64	68.06	624

Literature-anchored findings (GeneRIF, showing 3)

• Ocm plays a central role in inflammation-induced regeneration in the optic nerve. (PMID:21084621)
• Data indicate taht candidate genes ACTB, BZW, OCM, MACC1, NXPH1, PRPS1L1, RAC1 and RPA3, which lie within the DFNB90 region, were sequenced and no potentially causal variants were identified. (PMID:21734401)
• Deletion of oncomodulin in outer hair cells, leads to a progressive hearing loss in transgenic mice. (PMID:26843644)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	pvalb5	ENSDARG00000032836
mus_musculus	Ocm	ENSMUSG00000029618
rattus_norvegicus	Ocm	ENSRNOG00000001031

Paralogs (2): PVALB (ENSG00000100362), OCM2 (ENSG00000135175)

Protein

Protein identifiers

Oncomodulin-1 — P0CE72 (reviewed: P0CE72)

Alternative names: Parvalbumin beta

All UniProt accessions (1): P0CE72

UniProt curated annotations — full annotation on UniProt →

Function. Has some calmodulin-like activity with respect to enzyme activation and growth regulation. Binds two calcium ions.

Similarity. Belongs to the parvalbumin family.

RefSeq proteins (3): NP_001091091, NP_001378919, NP_001378920 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR008080	Parvalbumin	Family
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site

Pfam: PF13499

UniProt features (27 total): binding site 10, helix 7, turn 2, domain 2, strand 2, initiator methionine 1, chain 1, modified residue 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
1TTX	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0CE72-F1	92.31	0.89

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (10): 93; 95; 97; 102; 52; 54; 56; 58; 63; 91

Post-translational modifications (1): 2

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 35 (showing top): MORF_RAD51L3, chr7p22, YAMASHITA_METHYLATED_IN_PROSTATE_CANCER, MORF_BCL2L11, MORF_KDR, YAMASHITA_SILENCED_BY_METHYLATION, MORF_PTPRR, YOSHIMURA_MAPK8_TARGETS_UP, MORF_ERCC4, MORF_FSHR, ATM_DN.V1_UP, MORF_CAMK4, MIR6764_5P, MIR298, MORF_MAGEA9

GO Biological Process (0):

GO Molecular Function (3): calcium ion binding (GO:0005509), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
metal ion binding	1
binding	1
cation binding	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1541 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OCM	SLC26A5	P58743	896
OCM	PITPNM1	O00562	823
OCM	GFI1	Q99684	719
OCM	CALML6	Q8TD86	599
OCM	CALML4	Q96GE6	599
OCM	CALML3	P27482	598
OCM	CALML5	Q9NZT1	598
OCM	CALM1	P02593	588
OCM	CNTF	P26441	563
OCM	OTOF	Q9HC10	496
OCM	MYO7A	P78427	491
OCM	STRC	Q7RTU9	481
OCM	TECTB	Q96PL2	478
OCM	CALB2	P22676	476
OCM	POU4F3	Q15319	468

IntAct

11 interactions, top by confidence:

A	B	Type	Score
OCM	CKMT1A	psi-mi:“MI:0915”(physical association)	0.600
SDCBP	OCM	psi-mi:“MI:0915”(physical association)	0.560
WFDC1	OCM	psi-mi:“MI:0914”(association)	0.350
OCM	SDCBP	psi-mi:“MI:0915”(physical association)	0.000
OCM	CKMT1A	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): OCM (Affinity Capture-MS), SDCBP (Two-hybrid), CKMT1A (Two-hybrid), CKMT1B (Two-hybrid), OCM (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GWK0, O01305, O35508, P02613, P02615, P02616, P02624, P02626, P02627, P02629, P02630, P02631, P02637, P04109, P04110, P04111, P04573, P05941, P09485, P0CE71, P0CE72, P13833, P15844, P18087, P19753, P21788, P25027, P30187, P30563, P34368, P41045, P43305, P51434, P51879, P80026, P80050, P80079, P80080, P82978, Q03975

Diamond homologs: A0A1B0GWK0, A0A7M4EAX1, D3GME4, P02597, P02614, P02615, P02616, P02617, P02618, P02619, P02620, P02621, P02622, P02623, P02624, P02625, P02628, P02629, P02631, P04464, P05419, P05939, P05940, P05941, P09227, P0CE72, P19753, P20472, P28582, P30187, P30563, P32848, P43305, P49101, P51879, P53683, P56503, P59747, P80026, P80050

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	22
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

820 predictions. Top by Δscore:

Variant	Effect	Δscore
7:5882618:GAGCT:G	donor_gain	1.0000
7:5882620:GCT:G	donor_gain	1.0000
7:5882622:T:G	donor_gain	1.0000
7:5882622:T:TG	donor_gain	1.0000
7:5882626:G:GG	donor_gain	1.0000
7:5883996:GAGG:G	donor_gain	1.0000
7:5883997:AGGG:A	donor_loss	1.0000
7:5883998:GG:G	donor_gain	1.0000
7:5883999:GG:G	donor_gain	1.0000
7:5884000:GTAT:G	donor_loss	1.0000
7:5882489:TCAGA:T	acceptor_gain	0.9900
7:5882490:CAGA:C	acceptor_gain	0.9900
7:5882491:A:AG	acceptor_gain	0.9900
7:5882491:AGACC:A	acceptor_gain	0.9900
7:5882492:G:GG	acceptor_gain	0.9900
7:5882623:TAA:T	donor_gain	0.9900
7:5882624:AAGT:A	donor_loss	0.9900
7:5882625:AG:A	donor_loss	0.9900
7:5882626:G:C	donor_loss	0.9900
7:5882627:TAAG:T	donor_loss	0.9900
7:5884000:G:GG	donor_gain	0.9900
7:5882490:CA:C	acceptor_loss	0.9800
7:5882491:A:AC	acceptor_loss	0.9800
7:5882492:G:GT	acceptor_loss	0.9800
7:5882631:C:G	donor_gain	0.9800
7:5883885:TGTA:T	acceptor_loss	0.9800
7:5883886:GTA:G	acceptor_loss	0.9800
7:5883889:G:A	acceptor_loss	0.9800
7:5883889:GGT:G	acceptor_gain	0.9800
7:5883889:GGTTT:G	acceptor_gain	0.9800

AlphaMissense

733 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:5882573:T:C	F48L	0.992
7:5882575:C:A	F48L	0.992
7:5882575:C:G	F48L	0.992
7:5886067:T:C	F103S	0.989
7:5882574:T:C	F48S	0.985
7:5886066:T:C	F103L	0.985
7:5886068:C:A	F103L	0.985
7:5886068:C:G	F103L	0.985
7:5882622:T:C	L64P	0.984
7:5883966:G:C	D91H	0.983
7:5882519:T:C	F30L	0.982
7:5882521:C:A	F30L	0.982
7:5882521:C:G	F30L	0.982
7:5882585:G:C	D52H	0.981
7:5882520:T:C	F30S	0.980
7:5882504:T:C	F25L	0.978
7:5882506:T:A	F25L	0.978
7:5882506:T:G	F25L	0.978
7:5882586:A:T	D52V	0.978
7:5882597:A:C	S56R	0.978
7:5882599:C:A	S56R	0.978
7:5882599:C:G	S56R	0.978
7:5886067:T:G	F103C	0.978
7:5882586:A:C	D52A	0.977
7:5883952:T:C	L86S	0.977
7:5882622:T:A	L64H	0.976
7:5883967:A:C	D91A	0.975
7:5883906:T:C	F71L	0.974
7:5883908:T:A	F71L	0.974
7:5883908:T:G	F71L	0.974

dbSNP variants (sampled 300 via entrez): RS1000016704 (7:5864313 C>T), RS1000147379 (7:5880655 A>T), RS1000242653 (7:5880546 G>A,T), RS1000246806 (7:5860180 A>G), RS1000490188 (7:5885253 T>C), RS1000670716 (7:5876105 A>C), RS1000851964 (7:5859250 A>G), RS1001011604 (7:5863552 A>G,T), RS1001085816 (7:5867374 C>G), RS1001350108 (7:5863781 C>A,G,T), RS1001359883 (7:5859125 G>C), RS1001403567 (7:5873057 GACCCTGA>G), RS1001517851 (7:5861263 A>G), RS1001646378 (7:5869053 A>G), RS1001822649 (7:5882022 G>A,C)

Disease associations

OMIM: gene MIM:164795 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

5 total (human), top 5 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Amiodarone	increases expression	1
Benzo(a)pyrene	increases methylation	1
Cadmium	decreases expression	1
Valproic Acid	increases methylation	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.